A carregar...
Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble guanylate cyclase (sGC) stimulator riociguat. For...
Na minha lista:
| Publicado no: | Pulm Circ |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7074518/ https://ncbi.nlm.nih.gov/pubmed/30803329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894019837849 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|